RSS Feed ALL

Johnson & Johnson launches Generation Fine, a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

2 days ago

Generation Fine launches after global survey finds nearly 4 in 5 patients...

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

4 days ago

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab...

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease

4 days ago

TREMFYA® demonstrated significantly higher rates of combined fistula remission – complete external...

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

4 days ago

Study results represent a critical milestone for the investigational OTTAVA™ Robotic Surgical...

Promising Data from US Pilot Study Shows Planned Impella 5.5 Use is Safe and Feasible in Non-Shock, High-Risk Cardiac Surgery Patients

5 days ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

5 days ago

CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy...

Johnson & Johnson to Present New Data Spanning Vision Portfolio at ARVO 2026

5 days ago

• Seventeen company presentations highlight breadth of vision portfolio spanning myopia control...

STELARA® Pediatric Crohn’s Disease FDA Approval J&J Statement

8 days ago

Johnson & Johnson statement on investigational programs in large B-cell lymphoma

9 days ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

9 days ago

Johnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026

10 days ago

· Late-breaking Phase 3 PROTEUS data for ERLEADA® (apalutamide) selected to open...

Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference

12 days ago